Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer

BACKGROUND: Monosialotetrahexosylganglioside (GM1) is a neuroprotective glycosphingolipid that repairs nerves. Oxaliplatin‐based chemotherapy is neurotoxic. This study assessed the efficacy of GM1 for preventing oxaliplatin‐induced peripheral neurotoxicity (OIPN) in colorectal cancer (CRC) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, De‐shen, Wang, Zhi‐qiang, Chen, Gong, Peng, Jie‐wen, Wang, Wei, Deng, Yan‐hong, Wang, Feng‐hua, Zhang, Jian‐wei, Liang, Han‐lin, Feng, Fen, Xie, Chuan‐bo, Ren, Chao, Jin, Ying, Shi, Si‐mei, Fan, Wen‐hua, Lu, Zhen‐hai, Ding, Pei‐rong, Wang, Feng, Xu, Rui‐hua, Li, Yu‐hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943144/
https://www.ncbi.nlm.nih.gov/pubmed/31724334
http://dx.doi.org/10.1002/cam4.2693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943144/
https://www.ncbi.nlm.nih.gov/pubmed/31724334
http://dx.doi.org/10.1002/cam4.2693

Ejemplares similares